| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 04/03/1997 | WO1997012051A1 Pharmaceutical composition useful for nucleic acid transfection, and use thereof |
| 04/03/1997 | WO1997012048A1 Recombinant viruses incorporating a protease cleavable protein |
| 04/03/1997 | WO1997012017A1 Process for purifying alkoxylated fats |
| 04/03/1997 | WO1997011957A1 Conjugates of a polypeptide and a biocompatible polymer |
| 04/03/1997 | WO1997011719A2 Stereoselective delivery of chiral compounds |
| 04/03/1997 | WO1997011711A1 Iron dextran formulations |
| 04/03/1997 | WO1997011709A1 Anthelmintic macrocyclic lactone compositions |
| 04/03/1997 | WO1997011699A1 1,2,4-benzotriazine oxides formulations |
| 04/03/1997 | WO1997011688A1 Use of a vinyl acetate/n-vinyl-2-pyrrolidone copolymer in a transdermal matrix system |
| 04/03/1997 | WO1997011685A1 Method for synthesizing microcapsules of predetermined permeability |
| 04/03/1997 | WO1997011684A1 Use of heparinases to decrease inflammatory responses |
| 04/03/1997 | WO1997011682A2 Emulsion and micellar formulations for the delivery of biologically active substances to cells |
| 04/03/1997 | WO1997011681A1 Sustained release delivery system and long acting narcotic analgesics and antagonists |
| 04/03/1997 | WO1997011655A1 Implantable controlled release device to deliver drugs directly to an internal portion of the body |
| 04/03/1997 | WO1997011605A1 Stimulation of cell-mediated immune responses by targeted particulate genetic immunization |
| 04/03/1997 | DE19536504A1 Fluorierte Alkane und ihre Verwendung Fluorinated alkanes and their use |
| 04/03/1997 | DE19536394A1 Feste Arzneiformen, erhältlich durch Extrusion einer Isomalt enthaltenden Polymer-Wirkstoff-Schmelze Solid dosage forms obtainable by extrusion of an isomalt-containing polymer-drug melt |
| 04/03/1997 | DE19536165A1 Verfahren zur Reinigung von alkoxylierten Fetten A process for purifying alkoxylated fats |
| 04/03/1997 | CA2233343A1 Use of heparinases to decrease inflammatory responses |
| 04/03/1997 | CA2233280A1 Sustained release delivery system and long acting narcotic analgesics and antagonists |
| 04/03/1997 | CA2233278A1 Stimulation of cell-mediated immune responses by targeted particulate genetic immunization |
| 04/03/1997 | CA2232870A1 Method for synthesizing microcapsules of predetermined permeability |
| 04/03/1997 | CA2232669A1 Recombinant viruses incorporating a protease cleavable protein |
| 04/03/1997 | CA2231064A1 Pharmaceutical composition useful for nucleic acid transfection, and use thereof |
| 04/03/1997 | CA2230940A1 Emulsion and micellar formulations for the delivery of biologically active substances to cells |
| 04/02/1997 | EP0765664A1 Stable aqueous suspension of mesalazine for topical use |
| 04/02/1997 | EP0765659A1 Delayed drug-releasing microspheres |
| 04/02/1997 | EP0765357A1 Antiviral dendrimers |
| 04/02/1997 | EP0765173A1 A bio-erodible matrix for the controlled release of medicinals and the assay of hydrolytic enzymes |
| 04/02/1997 | EP0765163A2 Adjuvant compositions comprising a mineral salt and another immunostimulating compound |
| 04/02/1997 | EP0765151A1 Antibacterial oil-in-water emulsions |
| 04/02/1997 | EP0663951A4 Chitosan matrices for encapsulated cells. |
| 04/02/1997 | CN1146773A Porous particles aggregate and method therefor |
| 04/02/1997 | CN1146769A Method for stabilizing compound DX-52-1 and lyophilized composition thereof |
| 04/02/1997 | CN1146727A Segmented chelating polymers as imaging and therapeutic agents |
| 04/02/1997 | CN1146726A Block copolymers |
| 04/02/1997 | CN1146725A Gel for treatment of skin diseases and for disinfection of the skin |
| 04/02/1997 | CN1146722A Taxane class derivative based pharmaceutical compositions |
| 04/02/1997 | CN1146720A New pharmaceutical formulation and preparation process |
| 04/02/1997 | CN1146338A Stable cross-linked compound of polyvinyl pyrrolidone and iodine and method for preparation of said compound |
| 04/01/1997 | US5616690 Hexose derivatized human serum albumin clearing agents |
| 04/01/1997 | US5616689 Stabilizing the collagen fibers by reacting with stabilizing agent comprising polymeric material capable of causing collagen fibers to precipitate from solution |
| 04/01/1997 | US5616602 Skin disorders |
| 04/01/1997 | US5616588 Rapamycin formulation for IV injection |
| 04/01/1997 | US5616587 Aqueous risperidone formulations |
| 04/01/1997 | US5616565 Cyclodextrin cellular delivery system for oligonucleotides |
| 04/01/1997 | US5616343 Cross-linked amylose as a binder/disintegrant in tablets |
| 04/01/1997 | US5616335 Mixture of organic peroxy acid, copolymeric ethylene oxide-propylene oxide thickener and isocyanate, for applying to human or animal skins or mucous membranes |
| 04/01/1997 | US5616330 Taxine, a triglyceride, water and a surfactant; anticarcinogenic agent |
| 04/01/1997 | US5616311 Non-crosslinked protein particles for therapeutic and diagnostic use |
| 04/01/1997 | US5616246 Hydrophilic membranes for electrochemical devices and method for preparing same |
| 04/01/1997 | US5616123 Delivery of solid drug compositions |
| 04/01/1997 | US5616122 Methods and compositions for preventing secondary cataracts |
| 04/01/1997 | CA1339031C Method of preserving ophthalmic solutions and compositions therefor |
| 04/01/1997 | CA1339030C Glassy sugar matrix for controlled administration of beneficial agent |
| 03/27/1997 | WO1997011178A1 Human growth hormone variants |
| 03/27/1997 | WO1997011141A1 Fractionated vegetable oil |
| 03/27/1997 | WO1997011090A1 Inhibition of tumor growth |
| 03/27/1997 | WO1997010851A2 Nucleic acid delivery vehicle |
| 03/27/1997 | WO1997010850A1 Transcytosis vehicles and enhancers for drug delivery |
| 03/27/1997 | WO1997010849A1 Copolymeric micelle drug composition and method for the preparation thereof |
| 03/27/1997 | WO1997010847A1 Targeting of conjugates of poly(ethylene glycol) and antibodies against glutamic acid decarboxylase to islet cells |
| 03/27/1997 | WO1997010840A1 Anti-inflammatory antisense drug |
| 03/27/1997 | WO1997010828A1 Therapy for tissue membrane insufficiency |
| 03/27/1997 | WO1997010820A1 Stable vitamin c preparation |
| 03/27/1997 | WO1997010814A1 Propofol nanodispersions |
| 03/27/1997 | WO1997010812A2 Supersaturated transdermal drug delivery systems, and methods for manufacturing the same |
| 03/27/1997 | WO1997010811A1 Nanoparticles in photodynamic therapy |
| 03/27/1997 | WO1997010810A2 Pharmaceutical granules |
| 03/27/1997 | WO1997010809A1 Lyophilized thioxanthenone antimumor agents |
| 03/27/1997 | WO1997010806A1 Aerosol compositions |
| 03/27/1997 | WO1997010805A1 Ophthalmic compositions containing cyclodextrins and quaternary ammonium compounds |
| 03/27/1997 | WO1997001636A3 Recombinant mistletoe lectin |
| 03/27/1997 | WO1996040662A3 Aminooxy-containing linker compounds and their application in conjugates |
| 03/27/1997 | WO1996040082A3 Apparatus and method for delivering a biologically active compound into a biological environment |
| 03/27/1997 | WO1996039156A3 Phosphate-binding polymers for oral administration |
| 03/27/1997 | WO1996029974A3 Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules |
| 03/27/1997 | CA2658039A1 Human growth hormone variants |
| 03/27/1997 | CA2232834A1 Targeting of conjugates of poly(ethylene glycol) and antibodies against glutamic acid decarboxylase to islet cells |
| 03/27/1997 | CA2232444A1 Lyophilized thioxanthenone antitumor agents |
| 03/27/1997 | CA2231172A1 Nucleic acid delivery vehicle |
| 03/27/1997 | CA2230479A1 Transcytosis vehicles and enhancers for drug delivery |
| 03/27/1997 | CA2229285A1 Nanoparticles in photodynamic therapy |
| 03/26/1997 | EP0764659A1 Use of cyclodextrins and their derivatives for solubilising compounds of the Ginkgolide family |
| 03/26/1997 | EP0764439A2 Use of plant fats of foodstuff standard as emollient or consistency agent for cosmetics or pharmaceuticals |
| 03/26/1997 | EP0764172A1 Synthetic peptide analogs of lung surfactant protein sp-c |
| 03/26/1997 | EP0764170A1 Branched synthetic peptide conjugate |
| 03/26/1997 | EP0764032A1 Stable gel formulation for topical treatment of skin conditions |
| 03/26/1997 | EP0764031A1 Injectable formulations containing a desiccant |
| 03/26/1997 | EP0764020A1 Transdermal drug delivery system |
| 03/26/1997 | EP0764018A1 Non-steroidal anti-inflammatory ophthalmic suspensions |
| 03/26/1997 | EP0693963B1 Use of a transacylation reaction between an esterified polysaccharide and a polyamine to form a membrane at least on the surface of gelled particles in an aqueous medium, resulting particles, preparation methods therefor and compositions containing same |
| 03/26/1997 | EP0539493B1 Targeted drug delivery via phosphonate derivatives |
| 03/26/1997 | CN1146158A Colon-specific drug release system |
| 03/26/1997 | CN1146151A Intranasal antimigraine composition |
| 03/26/1997 | CN1146148A Ranitidine tablet having hydroxypropylmethyl cellulose containing coating and method for producing said coating |
| 03/26/1997 | CN1145907A Novel silicone derivatives,their production and use |
| 03/26/1997 | CN1145810A Taste modifier |
| 03/26/1997 | CN1145780A Rapidly disintegrating medicinal form of tramadol or tramadol salt |
| 03/26/1997 | CN1145779A Medicine matrix and its use |